← All trials
NCT06827899
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2027
- First posted
- Feb 14, 2025
- Last posted
- Feb 20, 2025
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Xiamen UniversityOfficial
- Fujian Provincial HospitalCollaborator
- Huizhou People's Central HospitalCollaborator
- Xiamen UniversitySponsor investigator
- Jieyang People's HospitalCollaborator
- Fujian Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.